When Slate Medicines launched early this year backed by a mega-round of financing, the company claimed best-in-class potential for its migraine drug candidate but offered few details. Now that Slate …
Health
-
-
In 2025, Medicare Advantage insurers denied 12% of standard prior authorization requests, Medicaid managed care insurers denied 14% and ACA Marketplace insurers denied 18%, according to a new analysis from …
-
Healthcare organizations are moving quickly to deploy AI tools, yet few are preparing for AI colleagues. Until now, healthcare has largely viewed AI as technology that supports human work. Ambient …
-
In the latest chapter of cost-control attempts, insurance companies are increasingly enforcing two strategies for patients who are currently on expensive medications: mandating re-authorization of those medications, and requiring that …
-
When discussing challenges in women’s health, two challenges that consistently rise to the forefront are limited funding and gaps in research. But a new Milken Institute report reveals another major …
-
The public markets welcomed another biotech company this past week with the $81 million stock market debut of Vogenx, a metabolic medicines developer whose in-licensed lead drug candidate is in …
-
At a life sciences conference earlier this year, a pharma analytics lead pulled me aside with what sounded like a simple question: “Is there an ICD-10 code for the disease …
-
AI scribes have freed physicians from having to type all throughout patient visits, but there’s still a lot of progress that needs to be made on the pile of administrative …
-
Jazz Pharmaceuticals, a company that built its place in epilepsy drugs through business deals, just struck another one: $820 million to buy Actio Biosciences, a startup whose lead program is …
-
Small group insurers are proposing a median 14% increase in premiums for 2027, according to a recent analysis from KFF and the Peterson Center on Healthcare. The report analyzed 295 …